Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients

Clicks: 140
ID: 117807
1970
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #70 of 85 articles by views in Annals of hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The majority of patients with acute myeloid leukemia (AML) are elderly, and their response to chemotherapy is poorer than that of younger patients. The combination of mitoxantrone (MTN) and cytosine arabinoside (Ara-C) is a possible alternative to an anthracycline/Ara-C combination for the treatment of AML in these patients. Of 52 older patients (> 59 years) referred over a 3.5-year period, 33 patients (age range 60–78 years, median 67 years) received MTN and Ara-C as therapy for newly diagnosed AML. MTN was administered at a dose of 12 mg/m2/day, intravenously, for 3 days (23 patients), or 10 mg/m2/day for 5 days (10 patients), and Ara-C at a dose of 100 mg/m2 twice daily, intravenously, for 7 days. Complete remission (CR) was achieved in 16/33 patients (48%). The median remission duration was 6 months (range 1–37 months). The median survival was 14 months for those who achieved CR compared with 9 months for those with resistant disease. Two patients remain in first CR after 13 and 37 months, but three patients died whilst receiving consolidation therapy. In selected elderly patients with AML, the combination of MTN and Ara-C provides an acceptable alternative to an anthracycline/ Ara-C regimen, with a higher CR rate than historical controls. However, the CR rate and remission duration remain low compared with those of younger patients, supporting the need to investigate new approaches to treatment in this population.
Reference Key
maccallum1970annalsmitoxantrone Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors P. K. MacCallum;A. Z. S. Rohatiner;C. L. Davis;J. S. Whelan;A. M. Oza;J. Lim;S. Love;J. A. L. Amess;M. Leahy;R. K. Gupta;C. G. A. Price;T. A. Lister;P. K. MacCallum;A. Z. S. Rohatiner;C. L. Davis;J. S. Whelan;A. M. Oza;J. Lim;S. Love;J. A. L. Amess;M. Leahy;R. K. Gupta;C. G. A. Price;T. A. Lister;
Journal Annals of hematology
Year 1970
DOI
doi:10.1007/BF01696230
URL
https://link.springer.com/article/10.1007/BF01696230
Keywords
oncology hematology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.